Stemcell United

Stemcell United EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Stemcell United (SCU.AX) as of Nov 16, 2026 is -1.48. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -1.62 — a change of -8.32% (higher).

EV/EBIT

-1.48

YoY

-8.32%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Stemcell United is 2022 -1.48 . EV/EBIT (Enterprise Value to EBIT) of Stemcell United was 2021 -1.62 . It decreases by -8.32% higher compared to the previous year.

The Stemcell United EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2015
-4.01 AUD
Jan 1, 2016
-4.02 AUD
Jan 1, 2017
-4.84 AUD
Jan 1, 2018
-2.12 AUD
Jan 1, 2019
-5.84 AUD
Jan 1, 2020
-3.00 AUD
Jan 1, 2021
-1.62 AUD
Jan 1, 2022
-1.48 AUD
The Stemcell United EV/EBIT history
YEAREV/EBITYoY
-1.48-8.32%
-1.62-46.10%
-3.00-48.61%
-5.84+175.57%
-2.12-56.23%
-4.84+20.48%
-4.02+0.17%
-4.01—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Stemcell United Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Stemcell United's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Stemcell United's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Stemcell United's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Stemcell United grows earnings faster than its peers.

Stemcell United Stock analysis

What does Stemcell United do? Stemcell United Ltd is an internationally operating company that is active in the field of stem cell research and therapy. It was founded in 2005 by British entrepreneur and scientist Dr. Samantha Phillips, who previously worked for the renowned Roslin Institute for Animal Genetics. The business model of Stemcell United is based on the development and distribution of innovative therapies that are based on the use of stem cells as a foundation. The company primarily relies on close collaboration with leading research institutions and clinics worldwide to stay up to date with the latest research and develop products and services that are based on current knowledge and meet the highest quality standards. The various divisions of Stemcell United include the development and production of stem cell-based therapies for diseases such as cancer, heart attack, dementia, and stroke. Additionally, the company also offers support and consultation in the field of clinical trials as well as training for doctors and researchers to improve and optimize the use of stem cell therapies. Another important area of Stemcell United's business activities is the production and marketing of stem cells for research purposes. Both embryonic and adult stem cells are produced and provided to advance research in this field and gain new insights. The products offered by Stemcell United mainly include stem cell preparations for wound healing and tissue regeneration, as well as specialized cell cultures for research in the field of stem cell therapy. These products are sold to clinics, research institutions, and end consumers and are available in many countries worldwide. In recent years, Stemcell United has become one of the leading companies in the field of stem cell research and therapy and enjoys a high reputation in the industry. The company primarily relies on close collaboration with other top companies in the industry and a strong connection to research and development in this field. Overall, Stemcell United is an innovative and dynamic company that sets standards in the field of stem cell research and therapy worldwide and constantly seeks new ways to utilize the possibilities of stem cell therapy for the health and well-being of humans and animals. Stemcell United is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Stemcell United stock

EV/EBIT (Enterprise Value to EBIT) of Stemcell United is -1.48 in 2022.

EV/EBIT (Enterprise Value to EBIT) of Stemcell United changed from -1.62 to -1.48, representing a -8.32% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Stemcell United since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Stemcell United with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Stemcell United

All Key Metrics — Stemcell United